Erik Magnus Ohman, MBBS

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 8678A Hafs Bldg, Durham, NC 27710
Phone (919) 681-2069
Email address ohman001@mc.duke.edu

Dr. Ohman, Professor of Medicine, received medical degrees from the Royal College of Surgeons in Ireland and the National University of Ireland (1984, Fellowship 1984-1987), and completed his training in cardiology at Duke University (1987-1991), where he has remained on faculty. In 2001, he became Chief of Cardiology at the University of North Carolina at Chapel Hill, where he founded the UNC Heart Center and became its first director. In 2005 he returned to Duke to pursue his interest in advanced coronary disease as the Director of the Program for Advanced Coronary Disease. Since that time, he has been appointed to Associate Director of the Duke Heart Center, the Kent and Siri Rawson Director for the Program for Advanced Coronary Disease, and most recently, Vice-Chair of Development and Innovation in the Department of Medicine.

Dr. Ohman’s clinical and research interests include interventional cardiology and high-risk supported PCI, and treatment of patients with advanced/complex coronary disease. He has researched how to improve patient care through the use of guidelines-based therapies and adherence, and examining global cardiovascular risk and health. He has been a participant on numerous guidelines writing committees, served on the ACC/AHA oversight committee for guidelines development, and has served on the steering committees for trials on ST-elevation myocardial infarction and non-ST-elevation ACS. He is a consultant to the National Institutes of Health, and a consultant for the FDA Advisory Panel for Cardiovascular Devices. 

Dr. Ohman has published over 600 peer-reviewed papers and three books in cardiovascular medicine. He holds three U.S. patents in reperfusion therapy. He is an associate editor for the American Heart Journal and serves on the editorial boards of the Journal of the American College of Cardiology and the American Journal of Cardiology.  He is a Fellow of the Royal College of Physicians in Ireland, the Royal Society of Medicine (U.K.), the European Society of Cardiology, the Society of Cardiac Angiography and Interventions, and the American College of Cardiology. 

Education and Training

  • M.B.B.S., Royal College of Surgeons (Ireland), 1981

Publications

Overlie, P. A., F. A. Shawl, R. A. Vogel, M. R. Mooney, S. C. Smith, S. Stertzer, R. J. Freedman, et al. “Failed angioplasty with cardiac arrest: Survival characteristics and outcomes from the national registry for emergency cardiopulmonary bypass investigators.” Chest 110, no. 4 SUPPL. (October 1, 1996).

Scholars@Duke

Granger, C. B., J. M. Miller, E. G. Bovill, A. Gruber, R. P. Tracy, M. W. Krucoff, C. Green, et al. “Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.” Journal of Intravenous Nursing 19, no. 3 (May 1, 1996): 147–56.

Scholars@Duke

Gurbel, P. A., F. I. Navetta, E. R. Bates, D. W. Muller, A. N. Tenaglia, M. J. Miller, B. Muhlstein, et al. “Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty..” Cathet Cardiovasc Diagn 37, no. 4 (April 1996): 382–91. https://doi.org/10.1002/(SICI)1097-0304(199604)37:4<382::AID-CCD8>3.0.CO;2-7.

PMID
8721695
Full Text

Mahaffey, K. W., C. B. Granger, R. Collins, C. M. O’Connor, E. M. Ohman, S. D. Bleich, J. J. Col, and R. M. Califf. “Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy..” Am J Cardiol 77, no. 8 (March 15, 1996): 551–56.

PMID
8610601
Scholars@Duke

Weaver, W. D., H. D. White, R. G. Wilcox, P. E. Aylward, D. Morris, A. Guerci, E. M. Ohman, et al. “Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators..” Jama 275, no. 10 (March 13, 1996): 777–82.

PMID
8598594
Scholars@Duke

Jurlander, B., P. Clemmensen, E. M. Ohman, R. Christenson, G. S. Wagner, and P. Grande. “Serum myoglobin for the early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction..” Eur Heart J 17, no. 3 (March 1996): 399–406. https://doi.org/10.1093/oxfordjournals.eurheartj.a014872.

PMID
8737214
Full Text

Anderson, R. D., and E. M. Ohman. “Succesful Identification and Management of High-Risk Patients with Acute Myocardial Infarction..” J Thromb Thrombolysis 3, no. 3 (1996): 271–78.

PMID
10613993
Scholars@Duke

Barsness, G. W., E. M. Ohman, R. M. Califf, D. J. Kereiakes, B. S. George, and E. J. Topol. “The thrombolysis and angioplasty in myocardial infarction (TAMI) trials: A decade of reperfusion strategies.” Journal of Interventional Cardiology 9, no. 2 (January 1, 1996): 89–115. https://doi.org/10.1111/j.1540-8183.1996.tb00604.x.

Full Text

Berger, P. B., D. R. Holmes, E. M. Ohman, M. A. O’Hanesian, J. G. Murphy, R. S. Schwartz, P. W. Serruys, and D. P. Faxon. “Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR)..” J Am Coll Cardiol 27, no. 1 (January 1996): 1–7.

PMID
8522681
Scholars@Duke

Barbagelata, A., C. B. Granger, E. J. Topol, S. J. Worley, D. J. Kereiakes, B. S. George, E. M. Ohman, J. D. Leimberger, D. B. Mark, and R. M. Califf. “Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group..” Am J Cardiol 76, no. 14 (November 15, 1995): 1007–13.

PMID
7484852
Scholars@Duke

Pages